Ensem Therapeutics, A Cbc Group-Incubated Biopharma Company, Raises $67 Million In Series A Financing To Develop Small Molecule Medicines For Difficult-To-Drug Targets

Apr 06, 2022•over 3 years ago

Amount Raised

$67 Million

Round Type

series a

BostonScience And EngineeringData And AnalyticsHealth CareSoftware

Description

ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc., and CBC Group, bringing the series A total to $67 million.

Company Information

Company

Ensem Therapeutics

Location

Boston, Massachusetts, United States

About

ENSEM is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas. ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets. For more information, please visit www.ensemtx.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Ensem Therapeutics, A Cbc Group-Incubated Biopharma Company, Raises $67 Million In Series A Financing To Develop Small Molecule Medicines For Difficult-To-Drug Targets

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information